Spakinect

Call Directions Website

Spakinect Discover the simplicity of our virtual good faith evaluations for medical spas. SpaKinect is a physician-owned Medical Corporation.

Our practitioners are compassionate and knowledgeable with expertise in the field of TeleHealth Medicine. We aim to provide excellence in quality, service, and support. SpaKinect offers the most robust TeleHealth solution on the market with proven success in the wellness center industry. Whether you’re starting a new telehealth program, increasing the scope of your current program, or simply want an effective, low-cost telemonitoring alternative, our Integrated Practitioner Services provide targeted, compassionate care that decreases wellness center costs and improves your patient’s visit. SpaKinect provides expert Telehealth practitioners that operate as a natural extension of your coordinated approval program. We serve as an integrated care team and combine the strengths of your local wellness center team with SpaKinect's centralized Telemedical expertise. The result is a highly effective, efficient, and scalable Telehealth program. SpaKinect can serve as your back-office, integrate your wellness approval protocols in our video conferencing and sophisticated electronic medical record software, and even generate approval letters in real time. By leveraging the latest breakthroughs in information technology, SpaKinect provides Telehealth and "cloud computing" systems with unparalleled advantages for wellness center medical professionals and clinicians. Our systems are designed to produce a digital standardized medical approval record that significantly reduces the cost of running medical wellness centers. Your clinic deserves knowledgeable and compassionate practitioners. From Start to Finish, your experience with SpaKinect will be simple, affordable and stress-free! SpaKinect's Telehealth practitioner experts can help you achieve your program outcome and ROI goals!

🚨 The FDA has added a new warning to Kybella’s label for injections outside the approved chin area.In September, the FDA...
10/16/2026

🚨 The FDA has added a new warning to Kybella’s label for injections outside the approved chin area.

In September, the FDA updated Kybella’s labeling and issued a Drug Safety Communication after reviewing adverse event reports and medical literature going back to the drug’s 2015 approval. Kybella is still approved for fat under the chin. But the label now states that using it outside that area is not approved and not recommended.

What was reported:
→ 129 cases involving injections outside the chin area, including blurred or reduced vision after injections around the eyes, muscle or nerve injury such as facial weakness, and abnormal sensation
→ 117 cases of nodules or masses that didn’t resolve, lasting about five months on average. These include injections both inside and outside the chin area, and some may need medical intervention.

Reports don’t confirm cause, but the label now carries clearer instructions. Providers should counsel patients on signs of nerve injury, difficulty swallowing, and serious injection-site reactions. Treatment should stop if a patient develops ulceration, necrosis, a nodule, a mass, or infection.

Off-label use isn’t illegal. But “not recommended” is now in writing, and if a patient has a reaction, the updated label is the first document anyone will check.

What to do now:
→ Review your Kybella protocols against the updated label
→ Update consent forms to reflect the new warnings
→ Brief injectors on when to stop treatment
→ Follow up on any nodule or mass
→ Report suspected reactions through MedWatch

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/fda-kybella-warning-injections-outside-approved-chin-area

🚨 The DOJ has charged two defendants with federal crimes for allegedly selling counterfeit Ozempic from China to U.S. di...
10/15/2026

🚨 The DOJ has charged two defendants with federal crimes for allegedly selling counterfeit Ozempic from China to U.S. distributors.

Last month, the DOJ announced the case after one defendant was extradited from Italy. Prosecutors say the product came from unauthorized sources in China and was sold to U.S. distributors at deeply discounted prices, with the aim of deceiving downstream customers into believing it was authentic.

According to prosecutors, the counterfeit included packaging, package inserts, and pen labels made to resemble the real product, along with needles whose sterility the FDA couldn’t verify. The alleged scheme ran from July 2023 to April 2024 and continued even after the FDA seized thousands of counterfeit units.

Each defendant faces six federal counts and up to 71 years in prison if convicted. An indictment is an allegation, and both are presumed innocent.

Why this matters for your practice:
Distributors sell to pharmacies and clinics, so a counterfeit sold to a distributor can reach a practice that never knew. A deep discount can be a red flag, and one enforcement action doesn’t mean the supply is clean.

What to do now:
→ Buy only from licensed, authorized sources
→ Keep purchasing records for every order
→ Question prices well below market
→ Check FDA counterfeit alerts regularly

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/doj-florida-counterfeit-ozempic-distribution-charges

If your injectors learned technique from a live demo, a new study is worth reading.A study in the Aesthetic Surgery Jour...
10/13/2026

If your injectors learned technique from a live demo, a new study is worth reading.

A study in the Aesthetic Surgery Journal asked 31 aesthetic experts and 218 conference attendees about live injecting, where injectors treat patients on stage in front of an audience. Most attendees were injectors themselves, and 92% had watched a live demo before.

The experts agreed on three risks:
→ 95.7% said injecting in front of an audience creates performance pressure
→ 93.1% said the audience can influence clinical decisions
→ 91.3% said less-experienced injectors may copy unsafe practices they see

The concern isn’t the injector on stage. It’s the conditions around them: stage lighting, camera angles, time limits, compressed protocols, and patient positions changed for visibility. Those don’t match a normal treatment room, and newer injectors may not know the difference.

Experts aren’t calling for an end to live demos. 76% supported continuing them, as long as clear safeguards are in place, including a written responsibility agreement, in-person clinical oversight, and patient follow-up.

What this means for your Med Spa:
→ Treat demo techniques as a starting point, not a protocol
→ Put responsibility in writing when a guest injector treats your patients
→ Keep consent separate from promotion or sponsorship
→ Follow up on demo patients like any other patient
→ Learn from demos with clear safeguards

The study measured expert opinion, not clinical outcomes, but it’s a useful check on how your team brings conference learning home.

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/aesthetic-surgery-journal-live-injecting-governance

🚨 Last month, Utah lawmakers reviewed a draft bill that would, for the first time in the state, legally define a Med Spa...
10/09/2026

🚨 Last month, Utah lawmakers reviewed a draft bill that would, for the first time in the state, legally define a Med Spa and set rules for who can perform services there.

The draft, Health Care Services Amendments, is under review for the 2027 session. It isn't law yet, and current requirements stay in place unless it passes. It builds on recommendations from Utah's Office of Professional Licensure Review, which flagged unclear Med Spa scope, gaps in medical-director oversight, and patient harm linked to compounding.

The draft would sort Med Spa services into three categories, based on the state's recommendations to lawmakers:

→ Minor cosmetic procedures: RNs, LPNs, and master estheticians under supervision
→ Cosmetic injections, like neurotoxins and fillers: delegated to RNs only, with a practitioner available within 60 minutes or 60 miles
→ Wellness injections, including nutrients, hormones, peptides, and medications: delegated to RNs only, with a practitioner on-site

Physicians, APRNs, and qualifying PAs would serve as responsible practitioners. Before most delegated services, they would need to evaluate the patient, in person or by telehealth, and create a patient-specific treatment plan.

Utah wouldn't be the first state to do this. Earlier this year, Indiana passed a law creating its own Med Spa category.

What to do now:
→ Sort your services into the draft's three categories
→ Check who performs your injections and whether they'd still qualify
→ Review how your practitioner is available during wellness injections
→ Follow the 2027 session for changes before a final vote

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/utah-med-spa-scope-injection-supervision-legislation

10/08/2026

"Patient says it's 'just lip filler.' Would you catch what they left out? 👀

In this reel, Dr. Anoshah Pierre, one of our Spakinect providers, walks through a real-world GFE scenario. A patient books hyaluronic acid lip filler. During the exam, they mention a past reaction to lidocaine, which they'd only ever connected to dental work.

Here's why that matters: many commonly used dermal fillers are formulated with lidocaine. A detail the patient almost didn't mention becomes the one that changes the treatment plan.

Caught during the GFE, the provider can follow protocol and make sure a suitable lidocaine-free option is considered and approved before treatment. If it's missed, it becomes an adverse event to manage after the fact.

A thorough, adaptive GFE adjusts based on the procedure and the patient. That documentation is what protects your clinic when the chart is reviewed. Spakinect has completed 1.5M+ GFEs with a 100% medical board audit pass rate.

Would you have caught it? Tell us the first follow-up question you'd ask 👇

📌 Save this for your next team training.

We work with 4,000+ Med Spas nationwide, delivering expert-led telehealth Good Faith Exams that protect your patients, your reputation, and your bottom line.

Learn more at spakinect.com

57.3% of U.S. Med Spas now advertise at least one medical service. For dermatology and plastic surgery practices, it's 2...
10/06/2026

57.3% of U.S. Med Spas now advertise at least one medical service. For dermatology and plastic surgery practices, it's 29.7%.

New research reviewed 14,748 Med Spa websites across the country to map what's actually being offered. Medical weight loss led at 40.1%, followed by IV therapy at 35.5%, hormone replacement at 18.9%, NAD+ at 13%, and peptide therapy at 11.4%.

The comparison is the part worth sitting with. Med Spas are listing these services at roughly twice the rate of physician-led aesthetic practices, and nearly four times the rate on IV and NAD+.

Why this matters for your practice:
Every service on that list requires a documented evaluation before treatment. Medical weight loss, IV, hormone replacement, NAD+, and peptides are all medical interventions, which means a provider has to assess the patient and record what they're cleared for before anything is administered.

Med Spas aren't adjacent to these services anymore. They're where most of them happen, and that's why the rules keep arriving. Nearly every enforcement action we've covered this year has landed on a service in that breakdown.

What to do with this:
→ Audit what your website advertises against what your license permits
→ Keep a documented evaluation on file for every medical service you offer, with what the patient was cleared for
→ Confirm the provider performing your evaluations is licensed in the patient's state
→ Know your state's rules on re-evaluating returning patients

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/new-research-maps-medical-services-us-med-spas

10/02/2026

A Med Spa owner's secret to stress-free compliance.

We love hearing from clients like Sky Cameron, NP. As a nurse practitioner and Med Spa owner, Sky recommends Spakinect to any practice that doesn't always have access to their medical director for GFEs.

See why 4,500+ Med Spa owners trust Spakinect: https://www.spakinect.com/

🚨 The FDA just issued another GLP-1 warning letter after reading the prescriptions. Some had no clinical justification.T...
09/29/2026

🚨 The FDA just issued another GLP-1 warning letter after reading the prescriptions. Some had no clinical justification.

The FDA issued a warning letter to a Houston compounding pharmacy following a November 2025 inspection, over compounded semaglutide and tirzepatide products the agency said failed to meet Section 503A conditions.

Section 503A limits compounding drugs that are essentially copies of approved products, unless a prescriber documents that a change makes a significant difference for a specific patient. The FDA examined those determinations.

What the FDA found in the prescriptions:
❌ Some contained no prescriber determination of a significant difference at all
❌ Others had determinations appearing verbatim across multiple records, which the FDA said suggested pre-generation
❌ The FDA flagged technology platforms that offer pre-selected statements for prescribers to choose from

The agency also cited recurring order volume from July through October 2025 as evidence the stated differences were pretextual. Separately, the letter cited insanitary conditions and CGMP violations involving sterile production, and stated affected products were adulterated and misbranded.

Why this matters for Med Spas: the letter went to the pharmacy, but the documentation the FDA reviewed came from prescribers. If your practice orders compounded GLP-1s, that's the paperwork under review.
→ Templated language is now a flagged pattern
→ Your ordering platform's dropdowns are part of the record
→ The determination has to be about one patient
→ Volume can undercut what the documentation claims

What to do now:
→ Know which of your GLP-1 products are compounded and which are FDA-approved
→ Look at what your prescribing platform actually generates on the order
→ Confirm each determination reflects that specific patient
→ Review your compounding pharmacy's sourcing and regulatory standing

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/fda-empower-pharmacy-compounded-glp1-warning-letter

🚨 Congress just introduced a bill that would stop corporate takeovers of medical practices, including MSO structures.On ...
09/28/2026

🚨 Congress just introduced a bill that would stop corporate takeovers of medical practices, including MSO structures.

On September 16, the U.S. House introduced H.R. 10444, the Stop Corporate Takeovers of Physicians Act of 2026. It proposes federal corporate practice of medicine restrictions covering who can own a medical practice and what a management services organization can do alongside one. The bill has been referred to the House Committees on Energy and Commerce and Ways and Means. It has not been enacted.

What the bill would restrict:
Practice ownership
→ Licensees would need majority ownership and a majority of the governing body
→ Owners would need to be licensed and present in the state where the practice operates
→ Owners would need to be substantially engaged in delivering medical care

MSO relationships
→ Limits on MSO roles in ownership, management, acquisition financing, and transfers of ownership interests
→ Management agreements negotiated independently, with compensation at fair market value
→ Limits on MSO authority over staffing, provider compensation, clinical policies, billing, pricing, and payer contracts
→ No advertising a medical practice's services under another entity's name

Why this matters for Med Spas: the MSO model is common in aesthetics, and Med Spas providing medical services can fall under medical practice requirements. Passive physician ownership wouldn't qualify. Brand naming could become a structural question. And the bill preserves state laws that impose equal or greater requirements, so state rules would apply on top.

What to do now:
→ Identify which of your services constitute the practice of medicine
→ Check your state's corporate practice of medicine requirements
→ Map who holds ownership, governance, and management roles in your structure
→ Review how administrative and clinical authority are divided under any MSO agreement
→ Track the bill's progress through committee

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/federal-bill-medical-practice-ownership-mso-restrictions

🚨 A patient allegedly consented to one product and received another. The operator faces three felony counts.A Miami Med ...
09/25/2026

🚨 A patient allegedly consented to one product and received another. The operator faces three felony counts.

A Miami Med Spa operator was arrested and charged in state court with three second-degree felony counts of unlicensed practice of a health care profession causing serious injury. Court filings allege the operator was not licensed to practice medicine in Florida. Written pleas of not guilty have been entered in both cases.

What the filings allege:
Case one, two counts. Two women reported hip and buttock injections with an unknown substance represented as Sculptra. Both identified the operator as the injector. The operator told investigators an RN performed the procedures.

Case two, one count. A woman reported abdominal fat-loss injections after she believed she was consenting to Sculptra 150. The filing alleges the injections involved Lemon Bottle, described as a foreign fat-dissolving substance.

The women reported abscesses, pain, scarring, repeated drainage procedures, and in one case repeated hospital treatment over roughly three months. All allegations remain pending in Miami-Dade County court.

Why this matters for your Med Spa: most unlicensed-injection cases turn on credentials. This one also turns on what was in the syringe, and on who could prove who held it.

How to protect your Med Spa:
→ Verify every injector holds the license required for the procedure
→ Confirm the identity, labeling, source, and FDA status of every product before use
→ Document who evaluates the patient, who injects, and who holds clinical responsibility
→ Match consent forms, records, and advertising to the product actually administered
→ Keep protocols for adverse reactions, follow-up care, and documenting complications

💡 Follow Spakinect for more industry insights designed specifically for Med Spa owners.

To read the full article, visit: https://www.spakinect.com/news/miami-med-spa-unlicensed-cosmetic-injections-arrest

Address

5405 Morehouse Drive Suite 170
San Diego, CA
92121

Opening Hours

Monday 8am - 7pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm
Saturday 8am - 6pm

Telephone

+18772668455

Website

Alerts

Be the first to know and let us send you an email when Spakinect posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category